Comparing the current results to its competitors, Rallybio reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 2.71 %, recorded in the same quarter.
Rallybio Corporation, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 13.21 %
September 23, 2024
Understanding FNAIT Risks Across Diverse Populations: Insights from Rallybio s Research Rallybio Corporation, a clinical-stage biotech firm based in New Haven, Connecticut, is set to unveil critical findings related to fetal and neonatal alloimmune thrombocytopenia (FNAIT) at the American Society of Human Genetics (ASHG) 2024 Annual Meeting. The company is focused on developing transformative therapies for patients dealing with rare and devastating diseases, and this presentation aims to shed light on the epidemiology of FNAIT within racially and ethnically diverse populations.FNAIT is a condition characterized by a low platelet count in neonates due to maternal antibodies targeting fetal platelet antigens. ...
June 17, 2024
Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse PopulationsNew Haven, Conn. (Date) - Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company dedicated to developing innovative therapies for patients with rare diseases, has recently released the topline results of an epidemiological analysis. The analysis evaluated the frequency of fetal and neonatal alloimmune thrombocytopenia (FNAIT) risk in different ancestral populations, highlighting the importance of assessing diverse ethnic and racial backgrounds in understanding this condition.FNAIT is a severe and potentially life-threatening condition where a pregnant woman s ...
May 9, 2024
In an exciting development, Rallybio Corporation, a clinical-stage biotechnology company focused on developing groundbreaking therapies for patients afflicted with rare diseases, has shared its financial results for the first quarter of 2024. In addition to showcasing impressive growth, Rallybio also provided valuable insights into its recent advancements. This article aims to outline the facts and assess their impact on the company s overall trajectory.Financial Results:Rallybio Corporation has reported significant strides in its financial performance during the first quarter of 2024. The company has demonstrated strong revenue growth, exemplifying its strategic approach to translating scientific advances i...
Context Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative cancer therapies. Their business model centers around the discovery and development of novel drugs that specifically target and inhibit the growth of hormone-driven cancers.
Forte Biosciences Inc is a biotechnology company focused on developing and commercializing innovative solutions for the treatment of dermatological diseases. Their business model centers around researching, developing, and bringing to market products that address unmet needs in the field of skin health through their proprietary technology platform.
Hutchmed China Limited operates on a vertically integrated platform, focusing on the discovery, development, and commercialization of targeted therapeutics for oncology and immunological diseases. The company employs a comprehensive business model that encompasses research and development, manufacturing, marketing, and sales in order to deliver innovative drugs to patients. By leveraging its internal capabilities and strategic partnerships, Hutchmed China aims to transform the treatment landscape and improve the lives of patients in China and around the world.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Sources:
Rallybio Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Rallybio Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
